Clearmind Medicine Inc. (CMND)

1.1701 +0.0001 (+0.01%) At close: 04:00PM EDT

Clearmind Medicine Inc.

1220 West 6th Avenue
Suite 101
Vancouver, BC V6H 1A5
Canada
604 260 1566
https://www.clearmindmedicine.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Adi Zuloff-Shani Ph.D.	Chief Executive Officer	N/A	N/A	1969
Mr. Alan Mark Rootenberg B.Com., B.Comm, C.A., CPA	Chief Financial Officer	N/A	N/A	1952
Prof. Mark Haden M.S.W.	Vice President of Business Development	N/A	N/A	1955
Mr. Gilad Babchuk	Head of Strategy & Communication	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Corporate governance

Clearmind Medicine Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.